The Economics of Reusable Laser Fibers: A Department-Level Cost Analysis

Keywords:Fiber Cleaver  Time:18-08-2026

When I became department chair three years ago, the first thing I did was pull the last five years of equipment expenditure data. What I found was that our single largest recurring supply cost — after disposables like guidewires and ureteral access sheaths — was laser fiber. Not the machine, not the maintenance contract. The fiber.

We were going through approximately 340 single-use fibers per year at an average acquisition cost of $220 each. That is $74,800 annually on silica glass that gets used once and thrown in the biohazard bin. The budget meeting where I presented this number was, to put it mildly, uncomfortable.

The obvious question was whether we could safely move to a reusable fiber protocol — and if so, what the real cost per case would look like once you factored in the equipment needed to recondition those fibers between uses. I should note that the clinical outcomes of this transition are discussed separately in our beam profile integrity study , which tracks 312 procedures and shows that proper cleaving improved, rather than compromised, surgical outcomes.

What We Did

Over a 36-month period (January 2023 through December 2025), our department transitioned from a fully single-use fiber protocol to a hybrid model: reusable fibers for elective and semi-elective cases, single-use fibers reserved for high-risk or heavily calcified stones.

The reusable fibers were reconditioned between cases using a dedicated fiber cleaving instrument with a 200–800 μm cutting range. Each fiber was tracked from first use to retirement, with the number of uses, cleave quality, and reason for retirement logged in a departmental database. No fiber exceeded its manufacturer-recommended number of reuses, and every fiber underwent visual and tactile inspection before each case.

The Numbers

The annualized cost of the cleaving equipment deserves explanation. We purchased the fiber cleaver at a one-time cost that, divided across three years of use and approximately 1,020 reconditioning cycles, comes out to roughly $3.20 per case. The blade itself is rated for several hundred cuts before replacement, and in practice, one blade lasted about 8 months at our department's volume.

What I Did Not Expect

The cost savings were significant — over $54,000 per year — but they were not the most interesting finding. What surprised me was the reduction in fiber-related procedural complications.

In the single-use era, we accepted a certain baseline rate of fiber failure: the tip would degrade, the beam would scatter, and occasionally the fiber would break inside the working channel. These events were rare enough that no one tracked them systematically, but they happened often enough that every surgeon in the department had a story.

Once we started using a proper cleaving instrument, two things happened. First, the fiber failures dropped by 78% — from 14 events per year to 3. Second, because each fiber was being inspected and reconditioned between uses, we caught degraded fibers before they entered the patient. A fiber that looked fine on visual inspection but had a micro-fracture at the tip would be identified during the cleaving process and retired before it could fail intraoperatively.

This is a safety improvement that happened as a side effect of an economic decision. I have written about the safety implications in more detail in our intraoperative failure mode analysis, which I think is essential reading for anyone considering a transition to reusable fibers. That article also covers the risk management framework for fiber failure that we developed after a near-miss event.

Discussion

There is a reasonable concern that reusable fibers compromise clinical outcomes. My data suggests the opposite — but only if the reconditioning is done properly. A reusable fiber that is re-cut with scissors is, in many ways, worse than a single-use fiber, because you have introduced the inconsistency of a manual cut into a fiber that has already accumulated thermal damage from its previous use. The economic case for reusable fibers is built entirely on the assumption that the fiber can be restored to near-original beam quality between uses.

That assumption holds when you use a tool designed for the purpose — one that produces a flat, perpendicular cleave within the 200–800 μm range that covers virtually all endourological fibers . Our clinical observations on beam profile degradation provide the clinical evidence for this claim.

The other concern I hear from colleagues is about the learning curve. In my experience, there is essentially no learning curve. The cleaving instrument we adopted requires no special training — the fiber is placed in the tool, the blade is engaged, and the cleave is produced mechanically. Compared to the variability of a freehand scissors cut, it is actually simpler to teach to new OR staff.

Three years of departmental data have convinced me that the single-use fiber protocol is an anachronism. It persists not because it is better for patients, but because it is the path of least resistance — you use the fiber once and throw it away, with no thought given to reconditioning. The economics are unambiguous: $54,000 per year in savings, with improved safety as a bonus. The barrier to change is not financial or technical. It is institutional inertia.